Table 3.

Results of main analysis, main analysis with truncation, and secondary per protocol analyses and competing risk analysis (adjusted HRs and 95% CIs are shown)

Cancer type							Secondary analyses
	Main analysis			Main analysis with truncation			Per protocol analysis			Per protocol with truncation			Competing risks analysis
	HR	95% CI		HR	95% CI		HR	95% CI		HR	95% CI		HR	95% CI
Any	1.16	1.02	1.32	1.15	1.02	1.31	1.18	1.04	1.34	1.17	1.03	1.34	1.17	1.03	1.33
Lung	1.28	0.89	1.83	1.26	0.88	1.81	1.29	0.90	1.86	1.28	0.89	1.83	1.28	0.89	1.83
Colon	0.84	0.62	1.13	0.83	0.61	1.12	0.85	0.63	1.15	0.84	0.63	1.14	0.85	0.63	1.14
Prostate	1.40	0.94	2.10	1.37	0.92	2.05	1.42	0.95	2.10	1.40	0.94	2.09	0.85	0.57	1.26
Bladder	1.07	0.76	1.52	1.06	0.75	1.50	1.09	0.77	1.54	1.08	0.76	1.53	1.08	0.76	1.53
Breast	1.05	0.66	1.69	1.06	0.66	1.69	1.09	0.68	1.73	1.11	0.69	1.76	0.87	0.40	1.92

Patients included in per protocol analyses: 8,387 in the DOAC cohort, 22,813 in the VKA cohort Median follow‐up in per‐protocol analyses: 2.62 years in the DOAC cohort (IQR: 1.72–3.62), 3.02 in the VKA cohort (IQR: 1.98–4.05).

CI, confidence interval; DOAC, direct oral anticoagulant; HR, hazard ratio; IQR, interquartile range; VKA, vitamin K antagonist.